« Back to Farmacia Journal 1/2024

BUFFERED AND NON-BUFFERED 4% ARTICAINE (1:100,000 EPINEPHRINE): CLINICALLY AND LABORATORY RESEARCH

TSVETAN TSVETANOV 1*, DESISLAV TOMOV 2

Download Full Article PDF

The research included 113 patients undergone mandibular nerve block with buffered and non-buffered 4% articaine, both contain 1:100,000 epinephrine. 67 patients (36 men, 31 women) were investigated with injected non-buffered anaesthetic as well as 46 patients (26 men, 20 women) with buffered analogue. Mean age of patients with injected 4% non-buffered articaine (1:100,000 epinephrine) was 42.96 ± 15.33 years, whereas mean age of patients with injected 4% buffered articaine (1:100,000 epinephrine) was 47.76 ± 16.20 years. The studied parameters were pain scores during injection according to Likert scale, latency period in seconds (speed of onset of anaesthesia), anaesthesia duration time in minutes and plasma levels (in mg/L) of buffered and non-buffered 4% articaine (1:100,000 epinephrine) and metabolite articaine acid in buffered and non-buffered 4% articaine (1:100,000 epinephrine) measured by liquid chromatography tandem mass spectrometry. No statistically significant difference in mean pain scores during injection with 4% buffered and non-buffered articaine (1:100,000 epinephrine) were determined. Buffered articaine provided faster anaesthesia onset, less duration of anaesthesia and showed lower plasma concentration of main anaesthetic and his metabolite articaine acid which is associated with possibilities for decrease anaesthetic toxicity.